Jens Huober, MD, professor of gynecologic oncology, Ulm University Hospital, discusses the de-escalation of treatments for patients with breast cancer.

Both escalation and de-escaltation will play a role in the future of breast cancer. There are ongoing trials investigating the de-escalation of radiotherapy, explains Houber.

However, there will also need to be scenarios of escalation in patients with triple-negative breast cancer. What is currently being investigated is adding to cisplatin-based chemotherapy to increase the efficacy.

Videos

Dr. Houber on the De-Escalation of Treatments for Breast Cancer

Jens Huober, MD, professor of gynecologic oncology, Ulm University Hospital, discusses selection criteria for adjuvant systemic therapy for patients with breast cancer

Not every patient should receive extended adjuvant endocrine treatment because it can be an overtreatment for many patients, explains Huober.

The best selection criteria currently available is the initial tumor size, particularly if the patient has node-positive or node-negative disease. Other biological adverse prognostic features, such as high-proliferation index or T3 tumors, are also potential selection criteria, states Huober.

Jens Huober, MD, professor of gynecologic oncology, Ulm University Hospital, discusses selection criteria for adjuvant systemic therapy for patients with breast cancer.

Jens Huober, MD

Articles

Dr. Houber on the De-Escalation of Treatments for Breast Cancer

Dr. Huober on Selection Criteria for Adjuvant Systemic Therapy for Breast Cancer